BCAB is the ticker symbol for BioAtla, Inc., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks BCAB with AI-powered analysis, an AI quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is BCAB a good stock to buy?

BCAB is tracked on 13F Pro with SEC EDGAR data, but is not currently included in our AI quality ranking. The full company profile with financials and AI insights is at https://13fpro.ai/company/BCAB.

Where does 13F Pro source BCAB data?

All BioAtla, Inc. fundamentals and ownership data come directly from SEC EDGAR. BioAtla, Inc. files with the SEC under CIK 1826892. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

BioAtla, Inc. BCAB

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Limited institutional coverage

Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 36 institutional filers currently hold this stock.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Top Institutional Holders

as of Q2 2026

$1.22M total

ACORN CAPITAL ADVISORS, LLC

$447.6K-98.0%

MILLENNIUM MANAGEMENT LLC

$292.4K-97.4%

Lido Advisors, LLC

$69.0KNew

Stonepine Capital Management, LLC

$68.0K-74.9%

ACADIAN ASSET MANAGEMENT LLC

$58.0K-98.8%

HRT FINANCIAL LP

$54.0KNew

GEODE CAPITAL MANAGEMENT, LLC

$53.1K-98.1%

DEUTSCHE BANK AG\

$43.7K-98.0%

BlackRock, Inc.

$39.8K-98.0%

VANGUARD CAPITAL MANAGEMENT LLC

$37.9K-99.4%

UBS Group AG

$25.7K-98.3%

VANGUARD FIDUCIARY TRUST CO

$19.6K-98.3%

MORGAN STANLEY

$4.6K-98.0%

Tower Research Capital LLC (TRC)

$3.6K-94.9%

SBI Securities Co., Ltd.

$1.1K-97.6%

Forum Finance Group S.A.

$1.0KNew

Twin Lakes Capital Management, LLC

$596-98.0%

JPMORGAN CHASE & CO

$464-6.2%

BARCLAYS PLC

$418New

JONES FINANCIAL COMPANIES LLLP

$147-98.0%

BNP PARIBAS FINANCIAL MARKETS

$29-98.5%

See all 21 institutional holders →

Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026

EDGAR

EPS (Diluted)

Q2 2026

EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/BCAB

Earnings Per Share

13fpro.ai/company/BCAB

Loading ratio trend…

BCAB key financials by period

Reported revenue, net income and operating margin by fiscal year, from BioAtla, Inc.'s annual filings on SEC EDGAR.

BioAtla, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Op. marginOperating margin
FY 2021	10-K	$300.0K	$-95.4M	—

Source: BCAB filings on SEC EDGAR →

BCAB insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

Sievers EricChief Medical OfficerShares withheld for tax or exercise price · Aug 31, 2026
Vasquez ChristianChief Financial OfficerShares withheld for tax or exercise price · Aug 31, 2026
Short Jay M PHDChief Executive OfficerShares withheld for tax or exercise price · Aug 31, 2026
Waldron Richard AFormer Chief Financial OfficerShares withheld for tax or exercise price · Feb 28, 2026

About BioAtla, Inc. (BCAB): stock profile, AI score and financials

BioAtla, Inc. (BCAB) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. BCAB is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 36 institutional filers currently hold this stock. Top institutional holders of BCAB by reported 13-F value include ACORN CAPITAL ADVISORS, MILLENNIUM MANAGEMENT, Lido Advisors, based on the most recent SEC filings. BCAB trades on the Nasdaq exchange and files with the SEC under CIK 1826892. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BCAB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BioAtla, Inc. directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1826892 →